Oxford Science Enterprises plc - 09 Sep 2026 Form 4/A - Amendment Insider Report for Barinthus Biotherapeutics plc. (BRNS)

Reporting relationship: former 10% owner
Issuer ticker: BRNS
Reported as of: 09 Sep 2026
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 11 Sep 2026, 11:00:41 UTC
Original report date: 06 May 2021
Prior SEC filing: 01 Oct 2025
Source filing: View source filing
Reporting owner signature: /S/Antonia Jenkinson

Key filing fact

Oxford Science Enterprises plc filed Form 4/A - Amendment for Barinthus Biotherapeutics plc. (BRNS) on 11 Sep 2026.

Key facts

This page summarizes Oxford Science Enterprises plc's Form 4/A - Amendment filing for Barinthus Biotherapeutics plc. (BRNS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 11 Sep 2026, 11:00.

Change

Previous filing in this sequence was filed on 01 Oct 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001856079 Primary reporting owner

Oxford Science Enterprises plc

Relationship: former 10% owner
Address: 46 WOODSTOCK ROAD, OXFORD, UNITED KINGDOM
Signature: /S/Antonia Jenkinson
Signature date: 09 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BRNS transaction

Ordinary Shares

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
Shares: -8,797,770
Change %: -100%
Price: $0.1110^*
Shares after: 0
Date: 09 Sep 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Oxford Science Enterprises plc is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

Ordinary Shares may be represented by American Depositary Shares, each of which represents one Ordinary Share.

Footnote F2

Pursuant to the terms of the Merger Agreement between Barinthus Biotherapeutics plc (the "Issuer") and Clywedog Therapeutics, Inc., the Issuer's board of directors has determined that each of the Issuer's outstanding Ordinary Shares (represented by American Depositary Shares) will be converted into the right to receive 0.111 shares of Beacon Topco, Inc.'s common stock, plus cash in lieu of any fractional shares resulting from the exchange, in accordance with the scheme of arrangement.

SEC remarks

In connection with the combination of Barinthus Biotherapeutics plc and Clywedog Therapeutics, Inc., Oxford Science Enterprises plc no longer beneficially owns more than 10% of the Issuer's Ordinary Shares, represented by American Depositary Shares. As a result, Oxford Science Enterprises plc is no longer subject to Section 16 of the U.S. Securities Exchange Act of 1934 with respect to the Issuer's Ordinary Shares and will no longer report transactions on Form 4 or Form 5.